Pharmaceutical and nutraceutical management of canine osteoarthritis: Present and future perspectives

被引:84
作者
Henrotin, Y
Sanchez, C
Balligand, M
机构
[1] CHU Sart Tilman, Inst Pathol, Bone & Cartilage Res Unit, B-4000 Liege, Belgium
[2] Univ Liege, Fac Med Vet, Dept Clin Sci, B-4000 Liege, Belgium
关键词
arthritis; cartilage; bone; glucosamine sulphate;
D O I
10.1016/j.tvjl.2004.08.014
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Osteoarthritis (OA) is one of the most common chronic musculoskeletal diseases and causes of lameness in the dogs. The osteoarthritic disease process involves the entire synovial joint, encompassing the synovium, cartilage and underlying bone. Joint failure results from an abnormal mechanical strain causing damage to normal tissue or failure of pathologically impaired articular cartilage and bone under the influence of normal physiological strain or a combination of both. In both cases, the end point is cartilage loss and joint impairment. Osteoarthritic chondrocytes show an altered phenotype characterised by an excess production of catabolic factors, including metalloproteinases and reactive oxygen species. These factors constitute potential therapeutic targets and some new drugs and nutraceuticals have been proposed to promote the return to homeostasis. Until now, the therapeutic management of OA in dogs has been dominated by nonsteroidal anti-inflammatory drugs, but some new compounds, including diacerhein, with potential structure-modifying effects, are already used to treat OA in humans and could be helpful to manage OA in the dog. In addition, novel nutraceuticals, such as avocado/soybean unsaponifiable substances, have shown symptomatic effects in knee OA in humans, and could offer an alternative to prevent OA progression. This paper provides an overview of recent discoveries in the pathophysiology and in the therapeutic management of osteoarthritis in dogs. (c) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:113 / 123
页数:11
相关论文
共 116 条
[31]   The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment [J].
Ghosh, P .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 1999, 28 (04) :211-267
[32]  
Gingerich DA, 2003, VET THER, V4, P56
[33]  
GOLDENBERG DL, 1982, J RHEUMATOL, V9, P204
[34]  
Guerassimov A, 1999, ARTHRITIS RHEUM, V42, P527, DOI 10.1002/1529-0131(199904)42:3<527::AID-ANR18>3.0.CO
[35]  
2-M
[36]   SOME RADIOGRAPHIC AND CLINICAL ASPECTS OF UNUNITED ANCONEAL PROCESS [J].
GUTHRIE, S .
VETERINARY RECORD, 1989, 124 (25) :661-662
[37]   Safety of Cartrophen Vet in the dog: review of adverse reaction reports in the UK [J].
Hannon, RL ;
Smith, JG ;
Cullis-Hill, D ;
Ghosh, P ;
Cawdery, MJH .
JOURNAL OF SMALL ANIMAL PRACTICE, 2003, 44 (05) :202-208
[38]   THE ASSOCIATION OF OBESITY WITH JOINT PAIN AND OSTEOARTHRITIS IN THE HANES DATA [J].
HARTZ, AJ ;
FISCHER, ME ;
BRIL, G ;
KELBER, S ;
RUPLEY, D ;
OKEN, B ;
RIMM, AA .
JOURNAL OF CHRONIC DISEASES, 1986, 39 (04) :311-319
[39]   The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives [J].
Henrotin, Y ;
Sanchez, C ;
Reginster, JY .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (01) :29-43
[40]   The role of reactive oxygen species in homeostasis and degradation of cartilage [J].
Henrotin, YE ;
Bruckner, P ;
Pujol, JPL .
OSTEOARTHRITIS AND CARTILAGE, 2003, 11 (10) :747-755